Two steps forward, one step back – news on access to CDKs in second line treatment
Hello everyone,
BCNA has an update on access to CDKs as second line treatment. Pfizer have this week advised BCNA about a new capped access program for the CDK inhibitor palbociclib (lbrance) which will be available from October 1, 2018.
This means you still have to pay for around 8 months of treatment (at a cost of around $40000) but after that time it will be free.
We understand that this is still a huge cost but it is an important step forward because people will at least know how much they will have to find should they want to proceed with this line of treatment.
BCNA is continuing to work for our members in this space and we’re very pleased to be able to advise that we have been able to negotiate with Pfizer that anyone who can show that they have already paid $40000 (for either first or second line treatment) can immediately move across to the capped program and no longer have to pay.
For further information, go to our website.
Please help us share the news to anyone you know who may currently be paying for Palbociclib.